Cargando…

The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets

l-DOPA is the gold-standard pharmacotherapy for treatment of Parkinson's disease (PD) but can lead to the appearance of troubling dyskinesia which are attributable to ‘false neurotransmitter’ release of dopamine by serotonergic neurons. Reducing the activity of these neurons diminishes l-DOPA-i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisher, Ria, Hikima, Atsuko, Morris, Rebecca, Jackson, Michael J., Rose, Sarah, Varney, Mark A., Depoortere, Ronan, Newman-Tancredi, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pergamon Press 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103782/ https://www.ncbi.nlm.nih.gov/pubmed/32057799 http://dx.doi.org/10.1016/j.neuropharm.2020.107997

Ejemplares similares

The 5-HT(1A) receptor biased agonists, NLX-204 and NLX-101, display ketamine-like RAAD and anti-TRD activities in rat CMS models
por: Papp, Mariusz, et al.
Publicado: (2023)

Multimodal imaging study of the 5-HT(1A) receptor biased agonist, NLX-112, in a model of L-DOPA-induced dyskinesia
por: Chaib, Sarah, et al.
Publicado: (2023)

Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model
por: Aboulghasemi, Nazanin, et al.
Publicado: (2018)

Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia
por: Pritchard, Sara, et al.
Publicado: (2017)

Molecular Signaling Mechanisms for the Antidepressant Effects of NLX-101, a Selective Cortical 5-HT(1A) Receptor Biased Agonist
por: Cabanu, Sharon, et al.
Publicado: (2022)

Neuroanatomical and Microglial Alterations in the Striatum of Levodopa-Treated, Dyskinetic Hemi-Parkinsonian Rats
por: Fletcher, Edward J. R., et al.
Publicado: (2020)

Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease
por: Goubault, Etienne, et al.
Publicado: (2020)

Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets
por: Michel, Anne, et al.
Publicado: (2017)

Photobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP
por: San Miguel, Mia, et al.
Publicado: (2019)

Dopamine D1 receptor signalling in dyskinetic Parkinsonian rats revealed by fiber photometry using FRET-based biosensors
por: Jones-Tabah, Jace, et al.
Publicado: (2020)

Amygdalo‐nigral circuit mediates stress‐induced vulnerability to the parkinsonian toxin MPTP
por: Cai, Hongwei, et al.
Publicado: (2023)

Age‐Related Parkinsonian Signs in Microdeletion 22q11.2
por: Boot, Erik, et al.
Publicado: (2020)

Alterations in Energy Metabolism, Neuroprotection and Visual Signal Transduction in the Retina of Parkinsonian, MPTP-Treated Monkeys
por: Campello, Laura, et al.
Publicado: (2013)

Deciduous DPSCs Ameliorate MPTP-Mediated Neurotoxicity, Sensorimotor Coordination and Olfactory Function in Parkinsonian Mice
por: Simon, Christopher, et al.
Publicado: (2019)

The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset
por: Huot, Philippe, et al.
Publicado: (2012)

PET Analysis of Dopaminergic Neurodegeneration in Relation to Immobility in the MPTP-Treated Common Marmoset, a Model for Parkinson’s Disease
por: Ando, Kiyoshi, et al.
Publicado: (2012)

Dysregulation of epithelial ion transport and neurochemical changes in the colon of a parkinsonian primate
por: Coletto, Erika, et al.
Publicado: (2021)

Neuroradiological and Neurophysiological Characteristics of Patients With Dyskinetic Cerebral Palsy
por: Park, Byung-Hyun, et al.
Publicado: (2014)

Rare Form of Dyskinetic Movements Associated with Alcohol Withdrawal
por: Prakash, Sathya, et al.
Publicado: (2016)

Quantitative Behavioral Assessment Methods for the Analysis of Graft-Induced Motor and Cognitive Function in the MPTP-Treated Parkinsonian Monkey
por: Taylor, J. R., et al.
Publicado: (1992)

IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates
por: Aron Badin, Romina, et al.
Publicado: (2013)

Correction: IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates
por: Aron Badin, Romina, et al.
Publicado: (2013)

Striatal Glutamate Release in l-DOPA-Induced Dyskinetic Animals
por: Nevalainen, Nina, et al.
Publicado: (2013)

Correction: Neuroradiological and Neurophysiological Characteristics of Patients With Dyskinetic Cerebral Palsy
por: Park, Byung-Hyun, et al.
Publicado: (2015)

Functional Connectivity Alterations in Children with Spastic and Dyskinetic Cerebral Palsy
por: Qin, Yun, et al.
Publicado: (2018)

The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial
por: Bonouvrié, Laura A., et al.
Publicado: (2019)

Aberrant Interhemispheric Functional Organization in Children with Dyskinetic Cerebral Palsy
por: Qin, Yun, et al.
Publicado: (2019)

Cardiac tyrosine hydroxylase activation and MB-COMT in dyskinetic monkeys
por: Cuenca-Bermejo, Lorena, et al.
Publicado: (2021)

Anti-inflammatory treatment induced regenerative oligodendrogenesis in parkinsonian mice
por: Worlitzer, Maik MA, et al.
Publicado: (2012)

A Comparative Pharmacokinetics Study of the Anti-Parkinsonian Drug Pramipexole
por: Putri, Ratih S. I., et al.
Publicado: (2016)

Catalpol Exerts a Neuroprotective Effect in the MPTP Mouse Model of Parkinson’s Disease
por: Wang, Li-Yuan, et al.
Publicado: (2019)

Protection and Repair of the Nigrostriatal Pathway with Stem-Cell-Derived Carotid Body Glomus Cell Transplants in Chronic MPTP Parkinsonian Model
por: Villadiego, Javier, et al.
Publicado: (2023)

Early infantile epileptic-dyskinetic encephalopathy due to biallelic PIGP mutations
por: Vetro, Annalisa, et al.
Publicado: (2020)

Use of the Dyskinesia Impairment Scale in non‐ambulatory dyskinetic cerebral palsy
por: Haberfehlner, Helga, et al.
Publicado: (2019)

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent
por: Ayoub, Bassam M., et al.
Publicado: (2018)

Parkinsonian Syndrome with Frontal Lobe Involvement and Anti-Glycine Receptor Antibodies
por: Endres, Dominique, et al.
Publicado: (2020)

Anti-Inflammatory and Neuroprotective Effects of Morin in an MPTP-Induced Parkinson’s Disease Model
por: Hong, Dong Geun, et al.
Publicado: (2022)

Cold Exposure After Exercise Impedes the Neuroprotective Effects of Exercise on Thermoregulation and UCP4 Expression in an MPTP-Induced Parkinsonian Mouse Model
por: Tsai, Yi-Ju, et al.
Publicado: (2020)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
por: Wang, Dengli, et al.
Publicado: (2022)

Clinical characteristics and functional status of children with different subtypes of dyskinetic cerebral palsy
por: Sun, Dianrong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lm6s8jc0vlabld4ic4a3udrdhv